Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach

The goal of this clinical trial is to learn if treatment modality including albumin-bound paclitaxel, oxaliplatin, tegafur,gimeracil and oteracil porassium capsules (SOX) and sintilimab works to treat locally advanced HER2-negative hepatoid adenocarcinoma of stomach. It will also learn about the safety of this modality. The main aim it aims to achieve are: * To evaluate the perioperative efficacy of albumin-bound paclitaxel combined with sintilimab and SOX in the treatment of locally advanced HER2-negative hepatoid adenocarcinoma of stomach * To evaluate the safety and long-term benefits of albumin-bound paclitaxel combined with sintilimab and SOX regimens in perioperative treatment of locally advanced HER2-negative hepatoid adenocarcinoma of stomach Participants will: * Preoperative treatment with abumin-bound paclitaxel, SOX and sintilimab for 4 cycles * Radical surgery after 4-6 weeks of the preoperative treatment * Adjuvant treatment with albumin-bound paclitaxel, tegafur,gimeracil and oteracil porassium capsules and sintilimab for 4 cycles

NCT Number	NCT07178340
Lead Sponsor	Peking University Cancer Hospital & Institute
Conditions	Hepatoid Adenocarcinoma of Stomach
Enrollment	30 participants
Start Date	2025-09-18
Primary Completion	2027-09-20 (estimated)
Study Completion	2028-09-20 (estimated)
Updated on ClinicalTrials.gov	2025-12-02